According to the Zhitong Finance App, Zaiding Pharmaceutical (09688.HK) announced results for the second quarter of 2026, with total revenue of US$106.3 million. Net product revenue for the second quarter of 2026 was $105.8 million. Net product revenue increased 11% month-on-month, thanks to Zelle's steady performance and continued growth in sales of Agamod. In the second half of 2026, the company looks forward to further stabilizing product sales, laying the foundation for a return to significant growth in 2027.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.